Cargando…
PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
Ejemplares similares
-
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
por: Kotmayer, Lili, et al.
Publicado: (2023) -
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
por: Takács, Ferenc, et al.
Publicado: (2022) -
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022) -
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
por: Varga, Gergely, et al.
Publicado: (2021) -
P1245: PARALLEL TESTING OF LIQUID BIOPSY (CTDNA) AND TISSUE BIOPSY SAMPLES REVEALS A HIGHER FREQUENCY OF TARGETABLE EZH2 MUTATIONS IN FOLLICULAR LYMPHOMA
por: Bátai, Bence, et al.
Publicado: (2023)